Advertisement

Search Results

Advertisement



Your search for Leena Gandhi, MD, PhD matches 9 pages

Showing 1 - 9


lung cancer

Researcher Supported by ASCO’s Conquer Cancer Foundation Earns Spot in Clinical Cancer Advances 2019 for Lung Cancer Study

The work of nine researchers who have previously received funding from Conquer Cancer is featured in ASCO’s Clinical Cancer Advances 2019. Visit CONQUER.ORG/CCA for more details. Immunotherapy At New York University Perlmutter Cancer Center in New York City, Leena Gandhi, MD, PhD, led a large...

lung cancer

Expert Point of View: John Heymach, MD, PhD, and Leena Gandhi, MD

“THIS STUDY represents a true milestone in the field of lung cancer. For the first time, the vast majority of patients with non–small cell lung cancer (NSCLC) can receive immunotherapy with pembrolizumab (Keytruda),” said ASCO expert John Heymach, MD, PhD, of MD Anderson Cancer Center, Houston,...

Leena Gandhi, MD, PhD, to Lead Lilly Immuno-Oncology

Eli Lilly and Company recently announced that Leena Gandhi, MD, PhD, a thoracic oncologist with a focus on immunotherapy and early drug development, will join Lilly Oncology in June 2018 to lead an immuno-oncology medical development. Dr. Gandhi is currently Director of Thoracic Medical Oncology...

lung cancer
immunotherapy

Pembrolizumab Plus Standard Chemotherapy Improves Survival in Newly Diagnosed Metastatic Non–Small Cell Lung Cancer

ADDING THE IMMUNE checkpoint inhibitor pembrolizumab (Keytruda) to standard chemotherapy with pemetrexed (Alimta) and a platinum as first-line therapy was superior to chemotherapy alone in the KEYNOTE-189 trial.1 Induction and maintenance therapies with the new triplet therapy improved overall...

Leena Gandhi, MD, PhD, Named Director of Thoracic Medical Oncology at NYU Langone’s Perlmutter Cancer Center

New York University (NYU) Langone Medical Center has announced the appointment of physician-scientist Leena Gandhi, MD, PhD, as Director of Thoracic Medical Oncology at its Laura and Isaac Perlmutter Cancer Center. In this new role, Dr. Gandhi will be tasked with building a robust program in lung...

skin cancer

PD-L1 Studied as Biomarker for Anti–PD-1 Immunotherapy

The anti–PD-1 inhibitor MK-3475 (formerly lambrolizumab) is in late-stage trials for advanced melanoma and is also being studied in other malignancies, including non–small cell lung cancer (NSCLC). An important aspect of Merck’s development program for MK-3475, as well as for other anti–PD-1 agents ...

lung cancer

Moving Forward in Non–Small Cell Lung Cancer: Targeted Combinations and Immunotherapy

The newer targeted therapies and immunotherapies have proven to be a boon to the treatment of lung and other cancers, but how best to deploy those therapies remains a burning question. Another important focus of current research is the identification and validation of biomarkers for these...

lung cancer

ASCO Endorsement of ACCP Guideline on Treating SCLC: Moving Forward to Better Outcomes in Oncology

In the current climate of rising health-care costs, particularly in the field of oncology, clinical guidelines provide a crucial tool to guide practitioners in evidence-based care and to improve the quality and consistency of care.1 The ASCO review and endorsement of the American College of Chest...

lung cancer

Study Identifies Potential Predictor of Clinical Outcome in Patients With Lung Cancer Treated With MK-3475

Among patients with non–small cell lung cancer (NSCLC) treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes, according to results of a phase I clinical trial presented at the American...

Advertisement

Advertisement



Advertisement